Skip to Content

'
Peter McLaughlin, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, U.T. M.D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit 429
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2006
Phone: 713/792-2860
Fax: 713/794-5656

Education & Training

Degree-Granting Education

1974 Tufts University School of Medicine, Boston, MA, MD
1970 Harvard College, Cambridge, MA, AB

Postgraduate Training

7/1978-7/1980 FELLOW, Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, Thomas Haynie, MD
7/1975-6/1977 RESIDENT, Internal Medicine, Hartford Hospital, Hartford, CT, Ralph Reinfrank, MD
7/1974-6/1975 INTERN, Internal Medicine, Hartford Hospital, Hartford, CT, Ralph Reinfrank, MD

Board Certifications

1984 ABIM, Hematology Subspeciality
1980 ABIM, Medical Oncology Subspeciality
1977 American Board of Internal Medicine

Honors and Awards

2007 Irwin H. Krakoff Award for Excellence In Clinical Research, Division of Cancer Medicine
2003 Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles
1. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagmemeister F, Romaguera J, Cabanillas F, Neelapu S, Banay R, Fayad L, Saville MW, Kwak L. Prospective trial of targeted radioimmunotherapy with Y-90 Ibritumomab Tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-714, 4/2009. e-Pub 1/2009. PMID: 19150940.
2. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol 27(6):904-910, 2/2009. PMID: 19114699.
3. McLaughlin P, Friedberg JW. Seeking wisdom from the Seer. Leuk Lymphoma 50(2):145-7, 2/2009. PMID: 19235008.
4. Schuster SJ, Venugopal P, Kern JC, McLaughlin P. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma 49(9):1681-1692, 9/2008. PMID: 18798103.
5. McLaughlin P, Vose JM. R-DHAP: A good small step, but not the journey's end. Leuk Lymphoma 49(6):1-3, 6/2008. PMID: 18452108.
6. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. 8-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide and rituximab. Blood 111(12):5530-5536, 4/2008. PMID: 18411419.
7. Liu Q, Fayad F, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee M-S, Ayala A, McLaughlin P. Improvment of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology 24(10):1582-1589, 2006.
8. McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma 47:965-966, 2006. PMID: 16840184.
9. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105:4573-4575, 2005. PMID: 15741224.
10. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol 21:2115-2122, 2003. PMID: 12775737.
11. McLaughlin P. Profiling: "Editorial on 'Survival after progression in patients with follicular lymphoma: analysis of prognostic factors'", by S. Montoto et al. (Ann Oncol 2002; 13: 523-30). Ann Oncol 13:499-500, 2002. PMID: 12056697.
12. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol 11:1551-1556, 2000. PMID: 11205462.
13. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27:37-41, 2000. PMID: 11225999.
14. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93(7):2202-7, 4/1999. PMID: 10090928.
15. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26:79-87, 1999. PMID: 10561022.
16. McLaughlin P. Treatment of follicular and other indolent lymphomas. Curr Opin Oncol 11:333-338, 1999. PMID: 10505768.
17. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998. PMID: 9704735.
18. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955-2960, 1998. PMID: 9531606.
19. Keating MJ, McLaughlin P, Cabanillas F. Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl) 6:21-26, 1997. PMID: 9460339.
20. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996. PMID: 8648382.
21. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 7:157-63, 1996. PMID: 8777172.
22. McLaughlin P. The role of interferon in the therapy of malignant lymphoma. Biomed Pharmacother 50:140-148, 1996. PMID: 8881370.
23. Besa PC, McLaughlin PW, Cox JD, Fuller LM. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 75:2361-2367, 1995. PMID: 7712449.
24. Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5 (Suppl 2):79-83, 1994. PMID: 8204523.
25. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5 (Suppl 2):73-7, 1994. PMID: 7515650.
26. McLaughlin P, Hagemeister FB, Swan F, Jr, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575-9, 1994. PMID: 8120556.
27. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F, Jr, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4:205-11, 1993. PMID: 7682436.
28. McLaughlin P. The role of interferon in the therapy of low grade lymphoma. Leuk Lymphoma 10:17-20, 1993. PMID: 8481666.
29. McLaughlin P, Fuller L, Redman J, Hagemeister F, Durr E, Allen P, Holmes L, Velasquez W, Swan F, Cabanillas F. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol 2 (Suppl 2):137-40, 1991. PMID: 1710918.

Last updated: 9/8/2009